DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Phase 3

Completed

Conditions: Non-segmental Vitiligo

Interventions: Drug: Ruxolitinib cream
Drug: Vehicle

First Posted Date: 2019-08-09

Last Posted Date: 2022-09-21

Lead Sponsor: Incyte Corporation

Target Recruit Count: 330

Registration Number: NCT04052425

Locations: 🇺🇸
Suny Downstate Medical Center, Brooklyn, New York, United States
🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸
Marvel Clinical Research Llc, Huntington Beach, California, United States

and more 54 locations

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2

Terminated

Conditions: Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Drug: Pemigatinib
Drug: Gemcitabine
Drug: Pembrolizumab
Drug: Carboplatin

First Posted Date: 2019-07-01

Last Posted Date: 2022-05-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 7

Registration Number: NCT04003610

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

and more 76 locations

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Phase 2

Terminated

Conditions: Advanced or Metastatic Solid Tumors
FGFR Translocations
FGFR Mutations

Interventions: Drug: Pemigatinib

First Posted Date: 2019-07-01

Last Posted Date: 2022-05-10

Lead Sponsor: Incyte Corporation

Target Recruit Count: 1

Registration Number: NCT04003623

Locations: 🇺🇸
Hawaii Cancer Care, Honolulu, Hawaii, United States
🇺🇸
FMH James M Stockman Cancer Institute, Frederick, Maryland, United States
🇺🇸
Ocala Oncology Center, Ocala, Florida, United States

and more 8 locations

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Phase 1

Terminated

Conditions: Bronchiolitis Obliterans Syndrome

Interventions: Drug: Itacitinib

First Posted Date: 2019-06-07

Last Posted Date: 2025-01-29

Lead Sponsor: Incyte Corporation

Target Recruit Count: 23

Registration Number: NCT03978637

Locations: 🇺🇸
Brigham and Women'S Faulkner Hospitals Inc, Boston, Massachusetts, United States
🇺🇸
Temple University Department of Thoracic Medicine and Surgery, Philadelphia, Pennsylvania, United States
🇧🇪
Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium

and more 6 locations

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Ruxolitinib cream

First Posted Date: 2019-04-19

Last Posted Date: 2020-02-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 41

Registration Number: NCT03920852

Locations: 🇺🇸
Orange County Research Center, Anaheim, California, United States
🇺🇸
San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States
🇺🇸
RM Medical Research, INC., Miami, Florida, United States

and more 7 locations

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1

Withdrawn

Conditions: Advanced and/or Metastatic Solid Tumors
Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma

Interventions: Drug: Retifanlimab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2019-04-19

Last Posted Date: 2020-04-24

Lead Sponsor: Incyte Corporation

Registration Number: NCT03920839

Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia

Conditions: Aplastic Anemia

First Posted Date: 2019-04-08

Last Posted Date: 2022-09-30

Lead Sponsor: Incyte Corporation

Registration Number: NCT03906318

Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

First Posted Date: 2019-04-08

Last Posted Date: 2019-04-08

Lead Sponsor: Incyte Corporation

Registration Number: NCT03906344

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

First Posted Date: 2019-04-08

Last Posted Date: 2022-04-19

Lead Sponsor: Incyte Corporation

Registration Number: NCT03906357

Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

First Posted Date: 2019-04-01

Last Posted Date: 2019-04-01

Lead Sponsor: Incyte Corporation

Registration Number: NCT03896815

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy